window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : January 20, 2026

  • News
  • About Us
Contact Us

small molecules

  • Artificial Intelligence,Biologics & Biosimilars,Drug Development,Movers & Shakers,Pharmaceuticals and therapeutics,Technology and platforms

    DaltonTx raises £4 million seed financing to build AI-enabled drug discovery platform

    DaltonTx, a UK-based technology company, has exited stealth mode and [...]

    September 23, 2025
  • Artificial Intelligence,Drug Development,Partnerships & Funding,Rare Diseases

    Evogene and Tel Aviv University join forces to tackle metabolite aggregation in metabolic diseases

    Evogene Ltd. has announced a scientific collaboration with Professor Ehud [...]

    August 12, 2025
  • CDMOs & Manufacturing,Global health,Regulatory Affairs,Research & Development,Supply Chain & Logistics,Technology and platforms

    Axplora expands Vizag API capacity and confirms FDA inspection success at Indian sites

    Axplora has announced a €6.5 million investment at its Vizag [...]

    August 6, 2025
  • Biologics & Biosimilars,CDMOs & Manufacturing,Drug Development,European biotech,Partnerships & Funding,Supply Chain & Logistics

    Ofichem expands drug substance capabilities with acquisition of Meribel Pharma Solutions’ Uppsala site in Sweden

    Acquisition enhances innovation offering and expands biotech footprint across Nordic [...]

    July 29, 2025
  • Artificial Intelligence,Drug Development,Partnerships & Funding

    Oxeltis and MFI join forces as $12.8 BN in silico drug discovery market accelerates

    Contract research firm Oxeltis and computational chemistry company Molecular Forecaster [...]

    June 30, 2025
  • CDMOs & Manufacturing,Regulatory Affairs,Supply Chain & Logistics

    Axplora’s Chasse-sur-Rhône site completes ninth consecutive regulatory inspection without critical remarks

    Axplora has confirmed the successful outcome of its latest inspection [...]

    June 8, 2025
  • Artificial Intelligence,CDMOs & Manufacturing,Clinical Trials,Drug Development

    Lonza launches Design2Optimize platform to accelerate API development

    Lonza has unveiled a new model-based development platform, Design2Optimize, which [...]

    May 23, 2025
  • CDMOs & Manufacturing

    New GMP-certified QC services bolster Swiss-based CDMO’s end-to-end offering

    April 29, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • AAVantgarde completes enrollment in LUCE-1 Phase 1 and Phase 2 trial of gene therapy AAVB-081 for Usher syndrome type 1B
    Categories: Biotech, Cell & Gene Therapy, Clinical Development, Clinical Trials, Opthalmology, Rare Diseases, Research & Development
  • Tjoapack expands oral solid dose bottle packaging capacity at Netherlands facility
    Categories: CDMOs & Manufacturing, Facilities and infrastructure, Pharmaceuticals and therapeutics, Supply Chain & Logistics
  • Vetter advances launch preparations for V-OVS next tamper-evident syringe closure system
    Categories: Biomanufacturing, CDMOs & Manufacturing, Drug Delivery & Formulation, Facilities and infrastructure, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top